TECNOTREE
19.9.2022 11:01:39 CEST | Business Wire | Press release
Tecnotree, a leading global Digital Transformation Partner for the Telecom Industry, is the first non-telco to be certified for real-world open API implementation on the leader board for TM Forum Open API Conformance. The certifications were carried out jointly with MTN in live operations within the MTN environment and demonstrated the successful implementation of Open APIs in commercial products and real-world deployments. Alignment to industry standards and best practices have been a part of Tecnotree’s DNA and its Digital Transformation strategy and proves Tecnotree’s commitment to industry standards, customers, and partner ecosystems. This landmark achievement makes Tecnotree the first Digital Platform Company among a list of CSPs like Verizon, Bell, and JIO, for certified real-world open API implementation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005054/en/
Tecnotree is the First Digital Platform Company in the World to be Certified for Real-World Open API Implementation by TM Forum (Photo: Business Wire)
Tecnotree’s Digital Platform powered with Open APIs using Open Digital Architecture enables quick and flexible integration to transform telecom business and operation models that extends beyond connectivity to monetise platform-based business models and partner ecosystems across verticals.
“We congratulate Tecnotree for being the first non-telco to achieve real-world certification for Open APIs deployed in live operation with MTN,” commented George Glass, CTO of TM Forum. “This is a path-breaking move by a software solutions provider and reaffirms Tecnotree’s commitment to open standards and their investment in next-generation product modernization. Tecnotree has been a great supporter of TM Forum’s work and is demonstrating the business value of Open APIs in enabling digital transformation for their customers.”
Monzer Ali, CTIO of MTN Uganda commented, “MTN and Tecnotree have been at the forefront of aligning with TM Forum frameworks (TAM, SID, Open APIs, eTOM) in our digital transformation journey. Tecnotree Digital BSS Suite is TMF ODA’s component-based architecture and is fully cloud-enabled, having an orchestration of micro-services capability that allows us to provide not only connectivity services for our subscribers but also digital services from adjacent industries, thus truly helping us monetize the power of 5G.”
Padma Ravichander, CEO of Tecnotree Corporation said, “This recognition is a true testimony of our journey as a pioneer in TM Forum’s Open API certification. Real-world Open API conformance and certification for Tecnotree is our commitment towards our customers to help them unlock and monetize the power of 5G with a range of digital products and services. These solutions can be provided to their customers, with seamless connectivity, speed, agility, and interoperability, on our Tecnotree Digital BSS platform. Our platform further enables operators to partner with the industry’s best ecosystem players to monetize B2B and B2B2X non-telco offerings by leveraging 5G for new digital multi-experiences.”
TM Forum Open API suite was developed in collaboration to drive IT agility, and digital business transformation. The certification recognizes how well your industry solutions, business processes, or open APIs align within the industry standards. They unlock a range of growth opportunities by providing exposure to new products and services while reducing cost and time to market. A large number of major global operators and vendors use the TM Forum Open API conformance, and the APIs are deployed all over the world.
About Tecnotree
Tecnotree is a 5G-ready digital Business Support System (BSS) player, with AI/ML capabilities and multi-cloud extensibility. Tecnotree is the first company in the world to be Platinum Certified by TM Forum Open API standards, and our agile and open-source Digital BSS Stack comprises the full range (order-to-cash) of business processes and subscription management for telecom and other digital services industries creating opportunities beyond connectivity. Tecnotree also provides Fintech and B2B2X multi-experience digital marketplace to its subscriber base through the Tecnotree Moments platform to empower digitally connected communities across gaming, health, education, OTT, and other vertical ecosystems. Tecnotree digital platform products and services today serve over 1 Billion Subscribers globally in over 70 countries. Tecnotree is listed on Helsinki Nasdaq (TEM1V).
For more information, please visit www.tecnotree.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom